<DOC>
	<DOCNO>NCT01807234</DOCNO>
	<brief_summary>The investigator propose test efficacy ketorolac nasal spray versus sumatriptan nasal spray versus placebo acute abortive therapy migraine head pain well migraine associate symptom include nausea allodynia .</brief_summary>
	<brief_title>Comparison Ketorolac Nasal Spray Sumatriptan Nasal Spray Placebo Acute Treatment Migraine</brief_title>
	<detailed_description>Participants randomize Ketorolac NS 31.5 mg , Sumatriptan NS 20 mg placebo treat three moderate severe migraine attack switch treatment attack received treatment . For treated attack ( moderate severe migraine attack ) , participant utilize two study treatment ( A B ) . Study treatment A administer one spray nostril , study treatment B administer one spray one nostril . Randomized Ketorolac , A=Ketorolac , B=Placebo Randomized Sumatriptan , A=Placebo , B=Sumatriptan Randomized Placebo , A=Placebo , B=Placebo</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Inclusion/Exclusion Criteria At Screening Visit , subject must meet follow criterion participate study : 1.1865 year age 2.Fulfills International Classification Headache Disorders ( ICHD ) II Criteria migraine note Table 1 3.History migraine least one year 4.Migraine onset prior age 50 year age 5.Headache frequency ( headache , migraine nonmigraine ) &lt; 9 day per month 6.At visit 2 , participant must report two headache day 28day runin period headache diary . 7.At least 48 hour freedom headache treated migraine attack . 8.If currently use headache preventive medication , must stable dose least 3 month prior enrollment throughout study period one prophylactic agent . 9.Able complete study procedure , include questionnaire ( assess demographic , headache characteristic , headache comorbidities medical history initial visit headache characteristic ) require headache calendar , study visit ; 10.Able understand , read sign inform consent ( English ) . 1 . Any condition ( history presence ) contraindicate use triptans NSAIDs include : Known hypersensitivity intolerance triptans NSAIDs Contraindications triptan use ( uncontrolled hypertension , ischemic heart disease , prinzmetal angina , cardiac arrhythmia , multiple risk factor atherosclerotic vascular disease , primary vasculopathies , basilar hemiplegic migraine ) Cerebrovascular disease except mild nonspecific white matter disease Peripheral vascular disease ischemic disease include myocardial infarction Uncontrolled hypertension ( systolic BP 160 mmHg diastolic BP 95 mmHg ( ) Migraine aura fulfil ICHDII criterion hemiplegic basilartype migraine Any history chronic renal hepatic impairment Use ergotaminecontaining medication monamine oxidase inhibitor Known suspect pregnancy , negative pregnancy test Lactation Bleeding dsycrasias include gastritis , peptic ulcer disease , gastrointestinal bleeding 2 . Physician diagnosis pain syndrome migraine 3 . Classification treatment resistant investigator 4 . Known drug substance abuse 5 . Any opioid use past 2 month 6 . Use medication , could interfere study assessment 7 . History noncompliance take medication ; 8 . Use experimental drug device within 30 day prior Screening Visit ( Visit 1 ) ; 9 . Any abnormal finding condition deem clinically significant investigator history , screening , physical exam contraindicates use triptans NSAIDs might interfere patient 's safety , study participation , might confound interpretation study result . 10 . Any history chronic renal hepatic disease already exclude number 1 ; plus see exclusion 9 . 11 . History chronic pulmonary disorder include nasal polyp ( see 1 ) asthma . 12 . History upper respiratory infection respiratory tract condition could interfere absorption nasal spray assessment AEs include rhinitis medicamentosa ( chronic daily use topical decongestant ) . 13 . History nasal surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>